| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022466440 |
| P356 | DOI | 10.1186/1471-2407-11-277 |
| P932 | PMC publication ID | 3144457 |
| P698 | PubMed publication ID | 21708009 |
| P5875 | ResearchGate publication ID | 51252506 |
| P2093 | author name string | Jing Li | |
| Ping Chen | |||
| Qingguo Li | |||
| Daorong Wang | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? | Q30856729 | ||
| Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer | Q33231041 | ||
| HER 2/neu protein expression in colorectal cancer | Q33242725 | ||
| Factors promoting tumor angiogenesis | Q33791689 | ||
| Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers | Q34274718 | ||
| Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial | Q34555503 | ||
| Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy | Q34743875 | ||
| c-erbB-2 is not a major factor in the development of colorectal cancer | Q36644043 | ||
| Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. | Q37121685 | ||
| Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis | Q37343653 | ||
| Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator | Q38471890 | ||
| Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer | Q38480006 | ||
| HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. | Q40291966 | ||
| ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells | Q40314359 | ||
| Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis | Q40865263 | ||
| Angiogenesis in the pathobiology and treatment of vascular and malignant diseases. | Q40878997 | ||
| Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis | Q41140259 | ||
| ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. | Q47950050 | ||
| Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. | Q53648066 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| Higher expression of oncoproteins c-myc, c-erbB-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors | Q60300155 | ||
| Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer | Q67484299 | ||
| Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon | Q69374824 | ||
| Tumor angiogenesis in primary and metastatic colorectal cancers | Q71591080 | ||
| Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer | Q73093342 | ||
| Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis | Q73507842 | ||
| Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients | Q73670868 | ||
| Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis | Q73841963 | ||
| Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer | Q74067245 | ||
| ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma | Q74455685 | ||
| Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival | Q77432075 | ||
| Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer | Q77585746 | ||
| Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer | Q79866807 | ||
| Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck | Q80342360 | ||
| Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival | Q81036858 | ||
| Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma | Q81392393 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 277 | |
| P577 | publication date | 2011-06-27 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas | |
| P478 | volume | 11 |
| Q41914792 | Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. |
| Q47803989 | Comparative pharmacokinetics study of anastrozole after single administration and combination with celecoxib |
| Q36770491 | Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer |
| Q26801167 | Correlation of human epidermal growth factor receptor protein expression and colorectal cancer |
| Q38087507 | Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. |
| Q37708062 | Death decoy receptor overexpression and increased malignancy risk in colorectal cancer |
| Q35957036 | Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis |
| Q53091400 | Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. |
| Q36184699 | Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country. |
| Q36119638 | Gene Expression-Genotype Analysis Implicates GSDMA, GSDMB, and LRRC3C as Contributors to Inflammatory Bowel Disease Susceptibility |
| Q33979049 | HER-2 overexpression and survival in colorectal cancer: a meta-analysis |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q89868898 | HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China |
| Q35211263 | HER2 in solid tumors: more than 10 years under the microscope; where are we now? |
| Q34029360 | Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas |
| Q34586892 | Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer |
| Q55227019 | Metastatic colonic and gastric polyps from breast cancer resembling hyperplastic polyps. |
| Q86876904 | Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor |
| Q38317180 | Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update |
| Q64116155 | Significance of HER2 protein expression and gene amplification in colorectal adenocarcinomas |
| Q34585338 | Significance of human epidermal growth factor receptor 2 expression in colorectal cancer |
| Q38018809 | The metastatic niche and stromal progression |
| Q54333943 | The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies. |
| Q38962587 | The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway |
| Q38069051 | VEGF levels and the angiogenic potential of the microenvironment can affect surgical strategy for colorectal liver metastasis |
Search more.